Keywords Troponin (I and T), high sensitive, gastro-intestinal, abdominal surgery, goal-directed therapy
|
|
- Linda King
- 5 years ago
- Views:
Transcription
1 Original Article Annals of Clinical Biochemistry 2014, Vol. 51(2) ! The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / acb.sagepub.com Peri-operative troponin monitoring using a prototype high-sensitivity cardiac troponin I (hs-ctni) assay: comparisons with hs-ctnt and contemporary ctni assays Graham R Lee 1, Shaman Jhanji 2, Heloise Tarrant 1, Steve James 3, Rupert M Pearse 3 and Maria Fitzgibbon 1 Abstract Background: Non-cardiac surgery is associated with major vascular complications and higher incidences of elevated plasma troponin (ctn) concentration. Goal-directed therapy (GDT) is a stroke volume (SV)-guided approach to intravenous (IV) fluid therapy that improves tissue perfusion, oxygenation and reduces post-operative complications. In patients undergoing major gastro-intestinal surgery, we compared high sensitive and contemporary troponin assays and correlated results with patient outcome. Methods: Patients (n ¼ 135) were randomized to receive IV fluid, guided by either the central venous pressure (CVP group, n ¼ 45) or SV ( dopexamine inotrope, n ¼ 45 per group). Serum was obtained pre- and post-operatively (0, 8 and 24 h) for troponin analysis by a prototype hs-ctni assay (Abbott Laboratories), hs-ctnt (Roche Diagnostics) and contemporary ctni (Beckman Coulter) assays. Results: All troponin measurements were increased (P ) post-operatively but there was no difference (P > 0.05) amongst treatments. Post-operative increases were reported more frequently (P ) and earlier with hs-ctni. Temporal increases (P ) were reported in patients with and without complications for hs-ctni/t assays but only in the complications group for ctni measurements. Elevations 599th centile occurred most often (P ) for hs-ctnt measurements but with similar frequency for both outcome groups (all assays). Only the hs-ctni assay showed an increased relative risk of mortality (P ) for elevations 599th centile Conclusions: Our study may suggest a possible preference for the hs-ctni assay in the peri-operative setting; however, our findings should be verified for larger cohort studies where emerging reference range data is incorporated for improving risk prediction with hs-ctn assays. Keywords Troponin (I and T), high sensitive, gastro-intestinal, abdominal surgery, goal-directed therapy Accepted: 17th May 2013 Introduction Cardiac troponin T and I (ctnt and ctni) are wellestablished cardiac-specific markers of myocardial cell damage. Superior sensitivity and specificity has augmented their universally preferred use, compared to 1 Department of Clinical Biochemistry and Diagnostic Endocrinology, Mater Misericordiae University Hospital, Dublin, Republic of Ireland 2 Critical Care Unit, Royal Marsden NHS Trust, London, UK 3 Barts and the London NHS Trust Royal, London, UK Corresponding author: Graham R Lee, Department of Clinical Biochemistry and Diagnostic Endocrinology, Mater Misericordiae University Hospital, Eccles Street, Dublin 9, Republic of Ireland (ROI). glee@mater.ie
2 Lee et al. 259 other biomarkers, in the diagnosis of acute myocardial infarction (AMI). 1 Prognostic value can also be obtained from peri-operative troponin measurements, as shown for asymptomatic patients in the VISION study (Vascular Events in Non-cardiac Surgery Patients), where the peak post-operative ctnt concentration was reported to be significantly associated with 30-day mortality. 2 In this patient cohort, where major vascular complications and a higher incidence of ctnt elevations (>99th centile) are reported post-operatively, 3 such elevations were detected more readily using the high-sensitivity (hs) ctnt assay. The possibility of evolving myocardial injury may also be determined for those patients with post-operative troponin elevations showing a temporal increase of more than a defined relative change (%). Evaluating serial troponin measurements against such changes may be used to improve the differentiation of any troponin elevations due to acute coronary syndrome from those due to chronic disease and non-cardiac conditions. 4 The latest generation of hs-ctnt and ctni assays now detect concentrations below the 99th centile with acceptable imprecision (CVs of 410%) and can therefore allow sub-clinical monitoring of possible myocardial remodelling and myocyte turnover. hs-ctn assays can also offer improved risk stratification by identifying patients with troponin concentrations greater than the limit of detection (LOD) but <99th centile, who are at an intermediate risk of major adverse cardiac events 5 and for whom intervention may alter risk and improve prognosis. We have extended previous work in the surgical setting for a cohort of patients undergoing major gastro-intestinal surgery. Patients were assigned to one of three post-operative interventions, two of which involved the goal-directed therapy (GDT) technique for intravenous (IV) fluid delivery, with or without inotropic support (Dopexamine (DOP)), as described by Jhanji et al. 6 GDT involves the measurement of cardiac output or of closely related variables such as oxygen delivery or stroke volume as treatment end points for the administration of IV fluid and/or inotropic support. GDT has thereby been shown to improve tissue perfusion, oxygenation, and reduce post-operative complication rates by possibly preventing tissue oxygen debt and organ dysfunction. 7 The vasoactive agent DOP has both vasodilatory and inotropic properties which may be used additionally to improve microvascular flow and further ameliorate outcome. In the current study, serial troponin measurements were obtained using the hs-ctnt assay (Roche Diagnostics), a contemporary ctni assay (Beckman Coulter) and a prototype hs-ctni assay from Abbot Laboratories, which we verified initially. All assays were compared for the detection of any peri-operative changes, treatment effects as well as their prognostic utility including risk prediction. Materials and methods Subjects This was a randomized, controlled, single-blinded intervention study involving adult patients (n ¼ 135) who were admitted to the intensive care unit (December 2007 to February 2009) following major elective gastro-intestinal surgery at the Barts and the London NHS Trust Royal, UK. Patients with a known history of acute myocardial ischaemia or acute arrhythmias were excluded. Other exclusion criteria are described previously. 6 Ethical approval, consent and patient data Details of ethical approval, consent, treatment allocations and clinical follow-up are described previously. 6 Approval for the analysis of cardiac markers at the Mater Misericordiae University Hospital (MMUH), Dublin (Ireland) was obtained from the hospital s ethics committee. Single-blinded analysis of cardiac markers was achieved using pseudo-anonymized (coded) samples and the transfer of patient-specific information to the MMUH following sample analysis. Clinical management: Intervention, monitoring and clinical outcome Post-operatively, IV fluid therapy (8 h) was guided by measurements of central venous pressure (CVP: control group, n ¼ 45) or stroke volume (SV). In this latter GDT group (n ¼ 90), 0.5 mg/kg/min of DOP was infused in half of the patients (SV þ DOP group: n ¼ 45, SV DOP group: n ¼ 45). Details of all perioperative therapeutic interventions, routine critical care, tissue perfusion and oxygenation monitoring have been described previously. 6 Assessment of patient outcome included recording the occurrence of any predefined post-operative complications (up to day 28): Renal (infection, acute kidney injury), gastro-intenstinal (paralytic ileus, ischaemia, anastomotic leak/stricture, peritonitis, infection [clostridium difficile], abdominal sepsis and GI haemorrhage), hepato-biliary (ischaemia, bile leak), respiratory (infection [pneumonia], pulmonary oedema/embolism, pleural effusion), circulatory (arrhythmia, angina, myocardial injury, cardiac arrest, heart failure, sepsis, shock and stroke), tissue (wound infection, haematoma). Mortality within 28 days (short term) and 180 days (intermediate term) of surgery was also recorded.
3 260 Annals of Clinical Biochemistry 51(2) Blood and plasma collection Patient blood (20 ml) was collected into serum separator tubes (Becton Dickinson, Cowley, UK) at several time points: pre-operatively, at baseline (0 h) and at 8 and 24 h post-operatively. Blood was centrifuged at 10,000 g, for 10 min, at room temperature. Serum was aliquoted and stored ( 70 C) until analysis. Laboratory methods (troponin analysis) Assay specifications. Cardiac TnT was measured using the hs-ctnt 5th generation assay (Lot ) on a Cobas analyser (Roche Diagnostics, Mannheim, Germany). Cardiac Troponin I (ctni) was measured using the AccuTnI 2nd generation assay on an Access 2 analyzer (Beckman Coulter, Fullerton, CA, USA), which our laboratory used for routine diagnosis and was verified previously. ctni was also measured using a prototype high-sensitivity STAT ctni assay (hs-ctni) on an ARCHITECT i1000sr analyser (Abbott Laboratories, IL, USA). Intra- and inter-assay imprecision for the hs-ctn assays was verified from replicate analysis (n ¼ 20 25) of Internal Quality Control (IQC) material: Preci-Control Troponin IQC (Roche Diagnostics) at two concentrations (30 and 2500 ng/l) and ARCHITECT High Sensitive Troponin I IQC (Abbott Laboratories) at three concentrations (20, 200 and 15,000 ng/l). Assay specifications are shown for all assays in Table 1. Sample analysis. Patient samples were mixed for 30 min (Rotamix) while thawing at room temperature (r.t.p.). Samples were centrifuged (10,000 g, 10 min at r.t.p.) and the supernatant was transferred to a secondary tube which was vortex-mixed before analysis. Assay reference ranges. The manufacturer s quoted 99th centile concentrations were used for the hs-ctnt and ctni assays (Table 1). For the hs-ctni assay, a 99th centile concentration of 25 ng/l was used. This was established in our laboratory from a different cohort of cardio-healthy patients (n ¼ 109) comprising 66 males and 43 females (median age [inter-quartile range (IQR)] of 37 years [29 49]), who were selected following a cardiology consult and with normal electrocardiography and echocardiography results (McGorrigan C, personal communication, January 2011). Data were assessed for normality (D Agostino þ Pearson omnibus test), and non-parametric analysis was used to determine the 99th centile concentration (Graphpad software, version 5). Statistical analysis Normality was assessed by the D Agostino and Pearson omnibus test. The Student s t-test was used for parametric data and the Wilcoxon Signed Rank or Mann- Whitney U tests (two-tailed) for non-parametric data. For non-parametric comparisons involving more than two groups, Friedman and Kruskal Wallis tests were used for paired and unpaired observations, respectively, followed by Dunn s Multiple Comparison test. Spearman rank was used for all data correlations. Troponin measurements were correlated to post-operative complications using logistic regression analysis. Categorical variables were analysed in contingency tables using Fisher s exact test and was used to calculate the relative risk of mortality (days 28 and 280) associated with peak peri-operative troponin measurements. P was considered significant for all analysis. For hs-ctnt measurements, data were adjusted Table 1. Assay specifications for ctni, hs-ctnt and prototype hs-ctni assays. Assay Limit of detection Concentration with CV <10% Concentration at 99th centile Imprecision (CV, %) Intra-assay Inter-assay ctni (ng/l) NA 15.6 (52) 2.71 (420) 4.42 (420) 2.75 (1340) 3.42 (1340) hs-ctnt (ng/l) (28) 3.4 (28) 1.7 (2049) 2.0 (2049) hs-ctni (ng/l) (20) 3.83 (20) 1.75 (200) 2.51 (200) 1.36 (15000) 1.88 (15000) NA: not available. Imprecision data are also given for hs-ctn assays. Values in brackets refer to concentrations at which imprecision was verified.
4 Lee et al. 261 (þ7 ng/l for concentrations 3 to <8 ng/l; þ5 ng/l between 8 and 20 ng/l) to reflect results obtained using reformulated new calibrated reagent lots. 8 Short-term increasing reference change values (RCVs) (log-normal), of 90% and 69% for the hs-ctnt and hsctni assays, respectively, were used as described previously. 9,10 Data were analysed using Prism (Graphpad software, version 5), Excel (Microsoft Office, 2007) and Medcalc (version ). Results Verification of the hs-ctnt and hs-ctni assays Both assays showed acceptable imprecision (CV 410% [hs-ctnt], CV 45% [hs-ctni]) for the range of concentrations assessed, including those comparable to the 99th centile (Table 1). Patient outcome The incidence of complications was similar (P ) for each treatment group (67% [CVP], 58% [SV] and 69% [SV þ DOP] of patients). Intra-operative tachycardia occurred more frequently (31% of patients) for the SV þ DOP group (P , 4% and 8% of patients in the CVP and SV groups); however, the incidence of cardiac complications was similar across treatment groups (9% [CVP], 7% [SV DOP]). Correlation of pre-operative troponin measurements with age and sex Age- and sex-related differences in concentration were observed only for the hs-ctnt assay (Figure 1). Only 5% of patients aged 460 years (n ¼ 2/36) had ctnt concentrations 5the 99th centile compared to 55% (n ¼ 52/99) of patients >60 years. The median (IQR) ctnt concentration was higher (P ) for males (13.8 ng/l, [ ng/l]) than females (10.2 ng/l, [ ng/l]). For only one patient were pre-operative concentrations 5respective 99th centile for all troponin measurements. Changes in post-operative troponin measurements: Effect of time and treatment For all treatment groups, troponin concentrations were greater (P ) at 24 h post-operatively, compared with pre-operative measurements (Figure 2) but there was no treatment differences (P > 0.05). Significant changes (P ) from pre-operative measurements were reported earliest (at 0 h) for the hs-ctni assay, irrespective of treatment. Characteristics of post-operative troponin changes and evaluation of measurements against the 99th centile The absence of any detectable peri-operative change was reported most frequently (P ) for ctni (Table 2) whereas temporal decreases and increases (P ) were observed most frequently for hs-ctnt and hs-ctni assays, respectively. The number of troponin results 5the respective 99th centile concentration was consistently higher for hs-ctnt measurements (Table 2). For ctni and hs-ctni, such elevations were reported most often for the SV þ DOP group and least so for the CVP group whereas for hs-ctnt the converse of this treatment effect was observed. Peri-operative troponin increases from pre-operative concentrations, to 5the 99th centile (at one or both time points), occurred most frequently (P ) for hs-ctnt (n ¼ 162) and least so (P ) for ctni (n ¼ 47) measurements (Table 2). Only 13% (21/162) of such hs-ctnt elevations were 5the RCV whereas 96% of such hs-ctni increases were also 5the respective RCV. Troponin increases to 5the 99th centile were again reported most frequently for the SV þ DOP group, for hs-ctni and ctni assays. Peri-operative troponin measurements and outcome Temporally significant troponin increases (P ) were observed for high-sensitivity assays, irrespective of outcome and occurred earliest (0 h) for hs-ctni (Figure 3). For ctni, only patients with complications showed significant increases, from 0 h onward. All troponin measurements tended to be higher at 24 h post-operatively for patients with than without post-operative complications in the GDT groups (Figure 3), particularly in the SV DOP group (P ). For both outcome groups, the peak peri-operative troponin concentration across all time points was >the LOD most frequently for the hs-ctni assay (Table 3). The proportion of patients with peak troponin results 5the respective 99th centile concentration was also similar (P ) for both outcome groups for all assays (Table 3). Logistical regression analysis did not show significant correlation to outcome at 28 days for any troponin variable (peri-operative increase or peak concentration/increase). For the hs-ctni assay, the relative risk (RR) of mortality within 28 days (3.67 [CI: ]) and 180 days (2.06 [CI: ]) of surgery was significantly greater (P ) for patients with a peak troponin concentration 599th centile. This was also true for unadjusted hs-ctnt measurements (28 days: 2.94 [CI: ]; 180 days: 2.12 [CI: ]) but not when
5 262 Annals of Clinical Biochemistry 51(2) Figure 1. Pre-operative concentrations of ctni (a), hs-ctnt (b) and hs-ctni (c) for all patients. Median (inter-quartile range) age ¼ 67 (60 76) years. The dashed line on each graph corresponds to the 99th centile concentration for each assay. Data were analysed using Spearman s Rank correlation.
6 Lee et al. 263 Figure 2. ctni (a-c), hs-ctnt (d-f) and hs-ctni (g-i) measurements for CVP, SV and SV þ DOP groups. Within each group, troponin concentrations were compared at each time point using Friedman and Dunn s post-test analysis. Data are presented as the mean S.E.M. Dashed lines correspond to the 99th centile. *P , **P , ***P vs. pre-op, # P , ## P , ### P vs. 0 h. Table 2. Peri-operative troponin changes and frequency of troponin elevations 599th centile. Serial measurement characteristics ctni ctni ctni hs-ctnt hs-ctnt hs-ctnt hs-ctni hs-ctni hs-ctni CVP SV SV þ DOP Total CVP SV SV þ DOP Total CVP SV SV þ DOP Total No change a Decrease b Increase c >99th centile d Increase þ >99th centile e Increase þ>99th centile þ >RCV NA NA NA NA RCV: reference change value. All changes involved comparisons to preoperative measurements. The total number of each observation recorded for each troponin assay were compared using Fisher s exact Test. Alphabets a e corresponds to a significant difference (P ) compared to the other two troponin measurements.
7 264 Annals of Clinical Biochemistry 51(2) Figure 3. Troponin analysis for patients with (striped bars) and without (solid bars) post-operative complications. Data are presented as the mean S.E.M. For combined treatment groups (top panel), times points were compared by Friedman (Dunn s post-test) and between outcome groups by two-way ANOVA (Bonferroni post-test) analysis. *P , **P , ***P vs. pre-op within each group. ## P vs. 24 h (non-complications). data were adjusted to reflect reformulated, new calibrated lots. For ctni, the RR only trended to significance over both time periods (28 days, P ¼ 0.08: 2.62 [CI: ], 180 days, P ¼ 0.07: 1.94 [CI: ]). Discussion In a cohort of patients undergoing major gastro-intestinal surgery, troponin was measured perioperatively using a prototype hs-ctni assay and
8 Lee et al. 265 Table 3. Summary of peak peri-operative troponin observations evaluated against the limit of detection (LOD) and 99th centile for patients presenting with and without complications. ctni Hs-cTnT hs-ctni Measurement type Non-complications Complications Non-complications Complications Non-complications Complications Number % Number % Number % Number % Number % Number % <LOD 24 51*** 39 44*** * >LOD to <99th >99th For comparisons within each outcome group, ***P vs. hs-ctn T/I assays, a P ¼ 0.06 vs. hs-ctni assay (Fisher s exact test). compared to contemporary ctni and hs-ctnt assays. Post-operative increases were reported more frequently with the hs-ctni assay and although all assays showed temporally significant increases, these occurred earliest for the hs-ctni assay. Significant changes were reported irrespective of post-operative outcome for hs-ctni (and hs-ctnt) measurements but only in patients with complications using the ctni assay. Although this may indicate discriminatory capability for the contemporary ctni assay, only the hs-ctni assay showed a significantly increased relative risk of mortality for elevations 599th centile. Measurements 599th centile were more frequent for the hs-ctnt assay but are likely confounded by age- and sex-related differences. Effects of GDT In an earlier report from this study, 6 improvements to oxygen delivery, microvascular flow and tissue oxygenation were observed for patients receiving stroke volume (SV)-guided fluid and DOP (SV þ DOP group). SV-guided therapy alone gave modest improvements in microvascular flow. Authors reported a possible improvement in renal function for both GDT groups (SV DOP) compared to the CVP-guided fluid group. Perhaps consistent with its beta adrenoreceptor effect, intra-operative tachycardia occurred most frequently in the SV þ DOP group. The incidence of cardiac complications was equal for both GDT groups. GDT did not reduce the overall complication rate in this study in contrast to previous similar studies; however, this study was not powered to identify differences in clinical outcomes. We did not find any significant treatment effect on troponin concentration, as Jhanji et al. 6 reported for serum inflammatory markers. This latter observation does not support a role for cardiac output-guided haemodynamic therapy in favourably influencing the systemic inflammatory response to tissue injury. Age- and sex-related effects with high-sensitivity troponin assays From pre-operative troponin measurements, age- and sex-related (male > female) differences were observed for the hs-ctnt assay (only) and agrees with previous reports. 11,12 Only 5% of patients 460 years of age had ctnt concentrations 5the 99th centile, compared to 55% of patients aged >60 years. Studies by Koerbin et al. 11 similarly reported a higher median ctnt for patients 560 years of age. Despite such demographic effects, we used only a single 99th centile concentration for the hs-ctnt (and ctni) assays, as quoted by the manufacturer. When our laboratory previously established the 99th centile concentration (25 ng/l) for the hs-ctni assay, age- or sex-related differences were not observed. Sex-related effects are though reported elsewhere for this hs-ctni assay, involving larger cohorts of subjects powered to detect gender differences. 13 Our 99th centile is though in good agreement with the Gutenberg Health Study (n ¼ 4139) 14 where a 99th centile of 24 ng/l was obtained, after excluding individuals with elevated N-terminal B-type Natriuretic Peptide (>95th centile). The effect of patient demographics reported using high-sensitivity troponin assays has raised concern regarding the correct interpretation of results, as part of the diagnostic options for patients presenting with ACS and in other clinical uses including the current setting. Rigorous definition of population reference ranges by age, sex and ethnicity has been proposed 15 with selection of cardio-healthy individuals based on physical examination, cardiac history, electrocardiogram and chest X-ray. 16 hs-ctn measurements are also required for patients who are clinically stable, with cardiovascular (CV) risk factors but no acute CV disease. Although such studies would be demanding, the information provided should promote optimal deployment of high-sensitive assays and reduce potentially inappropriate investigations.
9 266 Annals of Clinical Biochemistry 51(2) Peri-operative troponin monitoring The Vascular events In non-cardiac Surgery patients cohort evaluation (i.e. VISION) involves the study of patients with vascular complications following noncardiac surgery. This study has recently reported a significant association between the peak post-operative ctnt concentration and mortality, within 30 days of surgery. 2 This significant finding underpins the latest consensus on the universal definition of myocardial infarction, which recommends routine monitoring of cardiac biomarkers in high-risk patients, pre- and post- (48 72 h) major surgery. 17 In a sub-study of the VISION cohort, a higher incidence of ctnt elevations (>99th centile) was also reported in patients post-surgery and was detected more frequently using the hsctnt assay than its less-sensitive predecessor. 3 In our intervention study, we have extended work involving non-cardiac surgery patients, through a three-way comparison of hs-ctnt, ctni and hs-ctni assays and correlation of data to post-operative complications and mortality. Consistent with the findings by Kavsak et al., 3 we also report higher troponin concentrations post-operatively, irrespective of troponin measurement or treatment group. Temporally significant troponin increases were observed for all assays but occurred earliest for the hs-ctni assay. This finding may offer potential translation to therapeutic and prognostic benefit. In our study, post-operative troponin increases were also reported most often for hs-ctni and least so for the ctni assay where no detectable change was reported most frequently. These findings are supported by another study by Kavsak et al., 18 involving patients with ACS, where increases (significant) were reported more frequently for the hs-ctni assay (Beckman Coulter) compared to the contemporary ctni assay used currently, particularly for concentrations <99th centile. The ability of high-sensitivity assays to detect troponin at concentrations between the LOD and the 99th centile can offer additional prognostic value and risk stratification compared to less sensitive assays, by identifying patients who are at an intermediate risk of future cardiac events. 5 Troponin evaluations against the 99th centile and the RCV Unlike the earlier report by Jhanji et al., 6 where inflammatory markers were not evaluated against respective reference ranges, in the current study we considered all troponin measurements against each assay s 99th centile concentration. Such elevations were reported most frequently for the hs-ctnt assay, even prior to surgery, and are likely influenced by the age- and sex-related effects on concentration. By comparison, the hs-ctni and ctni assays were in closer agreement with each other, for all treatment groups, and showed discordant treatment effects compared to hs-ctnt measurements. These findings imply that assay concordance was dependent on the analyte, not assay sensitivity. Disparity between ctnt and ctni assays is not an isolated finding since in a previous study of dialysis patients, ctni was elevated (599th centile) less frequently (and less predictive of outcome) than ctnt. 19 In a subsequent study, 20 concordance between ctnt and ctni assays was shown to be concentration-dependent and better for comparisons at the LOD than at higher concentrations (i.e. CVs 410%). Authors also described how agreement between commercial ctni immunoassays for predicting outcome was dependent on the epitope specificity of capture and detection antibodies. By contrast with the present study, there were no comparisons at the respective 99th centile concentration. When we examined only those patients showing troponin increases from pre-operative values, to 599th centile concentration, again such increases were reported most frequently for the hs-ctnt assay. However, any assay comparisons at the 99th centile must be interpreted with caution since the ctni assay does not achieve desirable imprecision (i.e. 410% CV) at this threshold concentration. High sensitivity cardiac troponin assays are well documented for their ability to show evolving myocardial injury earlier than less sensitive assays and show greater diagnostic sensitivity even for baseline measurements. 18,21,22 However, since troponin may be raised in acute and chronic conditions affecting the myocardium, and by cardiac or non-cardiac related mechanisms, it is conceivable how this increased sensitivity may be offset by reduction in diagnostic specificity. Earlier we mentioned how the diagnostic specificity of highly sensitive assays may be improved by evaluating troponin elevations (599th centile) against the RCV (%), as reported recently for the differential diagnosis of AMI. 23,4 Accordingly, for the hs-ctnt assay 87% of increases (%) to 599th centile were less than the RCV. This was also true for more than half of patients when unadjusted data was analysed (data not shown). This implies that for a considerable proportion of patients with hsctnt increases 599th centile, such increases could be accounted for by analytical imprecision and biological variation. Such patients may therefore not merit the same investigation and management as for patients with increases 5RCV. The full implication of the recent reformulated recalibrated hs-ctnt assays is currently unknown as is the practicality of the existing 99th centile (14 ng/l). Extensive re-evaluation of previously published data and the outcomes obtained with this assay is likely. Although the RCV had little effect for hs-ctni measurements, recent studies using this
10 Lee et al. 267 prototype assay have demonstrated improved specificity for the diagnosis of AMI when a larger (266%: ROC-curve optimized) change criteria was included. 14 Peri-operative troponin and outcome Previous studies have shown that any troponin increase is associated with worse patient outcome 24 and higher risk for subsequent adverse events. 5 In the present study, troponin concentrations tended to be higher for patients with than without complications after 28 days of post-operative follow-up. However, logistical regression analysis did not show significant correlation of any troponin measurement to outcome. Patients showing peak elevations 5the respective LoD or 99th centile concentration (at 51 time point) were also similar between outcome groups, for all measurements, implying that troponin elevations were not predictive of such short-term outcome measures. However, when we considered the incidence of mortality within 28 days (10%) and 180 days (21%) of surgery, troponin concentrations 599th centile were associated with a significantly greater risk of mortality but only for hs-ctni measurements. This finding should though be verified for a larger cohort of patients. Although statistical significance was not obtained for the ctni assay, a recent meta-analysis involving vascular surgical patients and measurements with contemporary ctni assays show elevations (599th centile) to be strongly predictive of all cause mortality at 30 days post-surgery. 25 Our data support the recent recommendation 17 for routine postoperative troponin monitoring of patients post-surgery and the requirement for intervention studies to examine any potential for risk reduction in patients with postoperative troponin elevations. In conclusion, peri-operative troponin increases were detected earlier using the hs-ctni assay which may potentially confer therapeutic and prognostic advantage with this assay. Although the ctni showed discriminatory capability over both hs-ctn assays for patients with and without complications, only the hsctni assay predicted a significant risk of mortality for peak troponin elevations 599th centile. For hs-ctnt measurements, age- and sex-related effects possibly preclude the reliable routine use of a single 99th centile concentration and exemplify the need for reference range studies to inform optimal deployment of hs-ctn assays together with use of RCVs for serial measurements to enable appropriate patient stratification and intervention. Acknowledgements We thank Ms Kathleen Cafferkey and Mr Conor Russell (Department of Clinical Biochemistry þ Diagnostic Endocrinology, MMUH) for their technical support. SJ acknowledges UK National Health Service funding to the Royal Marsden/Institute of Cancer Research National Institute for Health Research Biomedical Research Centre. Declaration of conflicting interests None declared. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Ethical approval London Multi-Centre Research Ethics Committee, Medical and Healthcare products Regulatory Agency (UK), Mater Misericordiae University Hospital Ethics Committee, Trial registration number: ISRCTN Guarantor MF. Contributorship GL wrote the manuscript; HT was involved in analysing patient samples and GL was involved in data analysis; RMP and MF were involved respectively in conceiving the interventional protocol and analytical components of the study; SJh and RMP were involved in ethical approval, patient recruitment and collating patient data. SJa assisted patient data analysis. All authors reviewed and edited the manuscript and approved the final version of the manuscript. References 1. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007; 116: Devereaux PJ, Chan MT, Onso-Coello P, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012; 307: Kavsak PA, Walsh M, Srinathan S, et al. High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: a prospective cohort study. Clin Biochem 2011; 44: Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation 2011; 124: Schneider HG. How low can we go: high-sensitivity troponin T in patients presenting with chest pain. Ann Clin Biochem 2011; 48: Jhanji S, Vivian-Smith A, Lucena-Amaro S, et al. Haemodynamic optimisation improves tissue microvascular flow and oxygenation after major surgery: a randomised controlled trial. Crit Care 2010; 14: R151.
11 268 Annals of Clinical Biochemistry 51(2) 7. Pearse R, Dawson D, Fawcett J, et al. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial. Crit Care 2005; 9: R687 R Apple FS and Jaffe AS. Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: user beware. Clin Chem 2012; 58: Frankenstein L, Wu AH, Hallermayer K, et al. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clin Chem 2011; 57: Apple FS and Wu AHB. Short-term biological variation of cardiac troponin I measured with three high-sensitivity assays. Clin Chem 2011; 57: A Koerbin G, Tate JR and Hickman PE. Analytical characteristics of the Roche highly sensitive troponin T assay and its application to a cardio-healthy population. Ann Clin Biochem 2010; 47: Saenger AK, Beyrau R, Braun S, et al. Multicenter analytical evaluation of a high-sensitivity troponin T assay. Clin Chim Acta 2011; 412: Apple FS and Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58: Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 2011; 306: Wu A, Collinson P, Jaffe A, et al. High-sensitivity cardiac troponin assays: what analytical and clinical issues need to be addressed before introduction into clinical practice? Interview by Fred S. Apple. Clin Chem 2010; 56: Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004; 50: Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012; 60: Kavsak PA, MacRae AR, Yerna MJ, et al. Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin Chem 2009; 55: Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: Hickman PE, Koerbin G, Southcott E, et al. Newer cardiac troponin I assays have similar performance to troponin T in patients with end-stage renal disease. Ann Clin Biochem 2007; 44: Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361: Aldous SJ, Florkowski CM, Crozier IG, et al. Comparison of high sensitivity and contemporary troponin assays for the early detection of acute myocardial infarction in the emergency department. Ann Clin Biochem 2011; 48: Mueller M, Biener M, Vafaie M, et al. Absolute and relative kinetic changes of high-sensitivity cardiac troponin T in acute coronary syndrome and in patients with increased troponin in the absence of acute coronary syndrome. Clin Chem 2012; 58: Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007; 53: Redfern G, Rodseth RN and Biccard BM. Outcomes in vascular surgical patients with isolated postoperative troponin leak: a meta-analysis. Anaesthesia 2011; 66:
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better
10 Ways to Make the Use of High Sensitivity Cardiac Troponin Values Easier and Better Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department
More informationDefining rise and fall of cardiac troponin values
Defining rise and fall of cardiac troponin values Doable but Not Simple Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationTroponin when is an assay high sensitive?
Troponin when is an assay high sensitive? Professor P. O. Collinson MA MB BChir FRCPath FRCP edin MD FACB EurClin Chem Consultant Chemical Pathologist and Professor of Cardiovascular Biomarkers, Departments
More informationRapid exclusion of acute myocardial infarction in patients with undetectable troponin using a sensitive troponin I assay
Original Article Annals of Clinical Biochemistry 2015, Vol. 52(5) 543 549! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/0004563215576976 acb.sagepub.com
More informationACCESS hstni SCIENTIFIC LITERATURE
ACCESS hstni SCIENTIFIC LITERATURE 2017 2018 Table of contents Performance Evaluation of Access hstni A critical evaluation of the Beckman Coulter Access hstni: Analytical performance, reference interval
More informationSupplementary Online Content
Supplementary Online Content Rubini Giménez M, Twerenbold R, Boeddinghaus J, et al. Clinical effect of sex-specific cutoff values of high-sensitivity cardiac troponin T in suspected myocardial infarction.
More informationTable. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer.
Table. Analytical characteristics of commercial and research cardiac troponin I and T assays declared by the manufacturer. Commercially available assays - Company/ platform(s)/ assay LoB a LoD b 99 th
More informationHigh Sensitivity Troponin Improves Management. But Not Yet
High Sensitivity Troponin Improves Management But Not Yet Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationIFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid
IFCC Task Force on Clinical Applications of Cardiac Biomarkers (TF-CB) Report to the General Conference 2016 Madrid 1 CREATED By the EB in 2011, following to the Committee on Standardization of Cardiac
More informationUse of Biomarkers for Detection of Acute Myocardial Infarction
Use of Biomarkers for Detection of Acute Myocardial Infarction Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory Medicine
More informationDIAGNOSTICS ASSESSMENT PROGRAMME
DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Early rule out or diagnosis of acute myocardial infarction: High-sensitivity troponin tests (Elecsys troponin T high-sensitive, ARCHITECT STAT highsensitivity
More informationORIGINAL ARTICLE Determination of the 99th percentile upper reference limit for highsensitivity cardiac troponin I in Malaysian population
Malaysian J Pathol 2017; 39(2) : 135 140 ORIGINAL ARTICLE Determination of the 99th percentile upper reference limit for highsensitivity cardiac troponin I in Malaysian population Say Min LIM MD, Subashini
More informationHigh Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr.
High Sensitivity Troponins. IT S TIME TO SAVE LIVES. Updates from the ESC 2015 Guidelines November 17th 2016 OPL CONGRESS Dr. Marcel El Achkar Chairperson of Laboratory department Nini Hospital Lecturer
More informationConference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction: Diagnostic Implications
Conference Papers in Medicine, Article ID 583175, 5 pages http://dx.doi.org/10.1155/2013/583175 Conference Paper Small Changes in Cardiac Troponin Levels Are Common in Patients with Myocardial Infarction:
More informationLow concentrations of high-sensitivity troponin T at presentation to the
Title Page Low concentrations of high-sensitivity troponin T at presentation to the Emergency Department. Running head: Early rule-out using high-sensitivity troponin T Article Type: Letter to the Editor
More informationEDUCATIONAL COMMENTARY UNDERSTANDING THE BENEFITS AND CHALLENGES OF HIGH- SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS
SENSITIVITY TROPONIN TESTING IN CLINICAL AND PATHOLOGY SETTINGS Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationMario Plebani University-Hospital of Padova, Italy
Mario Plebani University-Hospital of Padova, Italy CK-MB mass assay CHF guidelines use BNP for rule out AST in AMI CK in AMI INH for CK-MB electrophoresis for CK and LD isoenzymes RIA for myoglobin WHO
More informationHigh-sensitivity cardiac troponin I immunoassay reduces the chance of patient misclassification in the emergency department
Original Article Page 1 of 5 High-sensitivity cardiac troponin I immunoassay reduces the chance of patient misclassification in the emergency department Giuseppe Lippi 1, Fabian Sanchis-Gomar 2,3,4, Rosalia
More informationAvailable online at
152 Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 45, no. 2, 2015 The Distribution of Abbott High-Sensitivity Troponin I Levels in Korean Patients with Chest Pain
More informationPeri-operative Troponin Measurements - Pathophysiology and Prognosis
Peri-operative Troponin Measurements - Pathophysiology and Prognosis Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine Chair, CCLS Division, Department of Laboratory
More informationBioRemarkable Symposium
BACC BioRemarkable Symposium Acute Myocardial infarction Stefan Blankenberg University Heart Center Hamburg London, September 7th, 2017 Universitätsklinikum Hamburg-Eppendorf Third Universal-Definition
More informationCardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray
Cardiac Troponin Testing and Chest Pain Patients: Exploring the Shades of Gray Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the acute
More informationDoes serial troponin measurement help identify acute ischemia/ischemic events?
Does serial troponin measurement help identify acute ischemia/ischemic events? Allan S. Jaffe, MD.* Consultant - Cardiology & Laboratory Medicine Professor of Medicine and Laboratory Medicine & Pathology
More informationHigh-Sensitivity Cardiac Troponin in Suspected ACS
15 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes STATE-OF-THE-ART High-Sensitivity Cardiac Troponin in Suspected ACS David A. Morrow, MD, MPH Director, Levine Cardiac Intensive Care
More informationSouth Afr J Anaesth Analg RESEARCH
Southern African Journal of Anaesthesia and Analgesia 2017; 23(3):64 68 https://doi.org/10.1080/22201181.2017.1317992 Open Access article distributed under the terms of the Creative Commons License [CC
More information7/31/2018. Overview of Next Generation Cardiac Troponin T High Sensitivity. Disclosures. Course Objectives: high sensitive Troponin T assay
Overview of Next Generation Cardiac Troponin T High Sensitivity Arleen Francis Medical & Scientific Liaison Roche Diagnostics 1 Disclosures Arleen Francis is an employee of Roche Diagnostics and a member
More informationImpact of Troponin Performance on Patient Care
Impact of Troponin Performance on Patient Care Linda C, Rogers PhD, DABCC, FACB Agenda Introduction Diagnosis of MI Guidelines Troponin Assay differences Classification of troponin assays Guideline acceptable
More informationTroponin Assessment. Does it Carry Clinical Message? Stefan Blankenberg. University Heart Center Hamburg
Biomarkers for Optimal Management of Heart Failure Troponin Assessment Does it Carry Clinical Message? Stefan Blankenberg University Heart Center Hamburg Congress of the European Society of Cardiology
More informationTROPONINS HAVE THEY CHANGED YOUR
TROPONINS HAVE THEY CHANGED YOUR PRACTICE THIS WEEK? Harvey White John Neutze Scholar Green Lane Cardiovascular Service and Cardiovascular Research Unit Auckland City Hospital, Auckland, New Zealand Disclosure
More informationA New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get from the Laboratory
e-issn 1643-3750 DOI: 10.12659/MSM.892033 Received: 2014.07.18 Accepted: 2014.08.14 Published: 2015.01.28 A New Generation of Biomarkers Tests of Myocardial Necrosis: The Real Quality a Physician can get
More informationhs-c Tn I high sensitivity troponin I <17 min
hs-c Tn I high sensitivity troponin I IFCC & ESC compliant 0/ h NSTEMI rule-out / rule-in algorithm POCT whole blood/plasma Results in < 7 minutes
More informationThe Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients
The Journal of International Medical Research 2003; 31: 76 83 The Diagnostic Value of Troponin T and Myoglobin Levels in Acute Myocardial Infarction: a Study in Turkish Patients S VATANSEVER 1, V AKKAYA
More informationDiagnostics consultation document
National Institute for Health and Care Excellence Diagnostics consultation document Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive,
More informationDocument Version Publisher s PDF, also known as Version of Record (includes final page, issue and volume numbers)
Variation of cardiac troponin I and T measured with sensitive assays in emergency department patients with noncardiac chest pain Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.H. Published
More informationHigh-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018 High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial Professor
More informationEarly-goal-directed therapy and protocolised treatment in septic shock
CAT reviews Early-goal-directed therapy and protocolised treatment in septic shock Journal of the Intensive Care Society 2015, Vol. 16(2) 164 168! The Intensive Care Society 2014 Reprints and permissions:
More informationDiagnostics guidance Published: 1 October 2014 nice.org.uk/guidance/dg15
Myocardial infarction (acute): Early rule out using high-sensitivity troponin tests (Elecsys Troponin T high-sensitive, e, ARCHITECT STAT T High Sensitive Troponin-I and AccuTnI+3 assays) Diagnostics guidance
More informationPreparing the United States for High-Sensitivity Cardiac Troponin Assays
Journal of the American College of Cardiology Vol. 61, No. 17, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.069
More informationFluid bolus of 20% Albumin in post-cardiac surgical patient: a prospective observational study of effect duration
Fluid bolus of 20% Albumin in post-cardiac surgical patient: a prospective observational study of effect duration Investigators: Salvatore Cutuli, Eduardo Osawa, Rinaldo Bellomo Affiliations: 1. Department
More informationStatistical Analysis Plan
The BALANCED Anaesthesia Study A prospective, randomised clinical trial of two levels of anaesthetic depth on patient outcome after major surgery Protocol Amendment Date: November 2012 Statistical Analysis
More informationRapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R.
Rapid detection of myocardial infarction with a sensitive troponin test Scharnhorst, V.; Krasznai, K.; van 't Veer, M.; Michels, R. Published in: American Journal of Clinical Pathology DOI: 10.1309/AJCPA4G8AQOYEKLD
More informationNon-commercial use only
Emergency Care Journal 2019; volume 15:7798 Determinants of troponin T and I elevation in old patients without acute coronary syndrome Antonio Di Micoli, 1 Chiara Scarciello, 1 Stefania De Notariis, 1
More informationWhat can we learn from EQAs and audits for cardiac marker testing?
What can we learn from EQAs and audits for cardiac marker testing? Dr P. O. Collinson MA MB BChir FRCPath MD FACB Consultant Chemical Pathologist and Director of Clinical Blood Sciences, Head of Vascular
More informationPost Operative Troponin Leak: David Smyth Christchurch New Zealand
Post Operative Troponin Leak: Does It Really Matter? David Smyth Christchurch New Zealand Life Was Simple Once Transmural Infarction Subendocardial Infarction But the Blood Tests Were n t Perfect Creatine
More informationHigh-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective Evaluation
Clinical Chemistry 61:7 983 989 (2015) Proteomics and Protein Markers High-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective
More informationWaiting for High-Sensitivity POCT Cardiac Troponin Assays: Clinical and Analytical Needs I Have a Pain in My Chest That Hurts Very Bad
Waiting for High-Sensitivity POCT Cardiac Troponin Assays: Clinical and Analytical Needs I Have a Pain in My Chest That Hurts Very Bad Fred Apple PhD Hennepin County Medical Center University of Minnesota
More informationThe state-of-the-art of high-sensitivity immunoassay for measuring cardiac troponin I and T
Editorial Page 1 of 5 The state-of-the-art of high-sensitivity immunoassay for measuring cardiac troponin I and T Aldo Clerico 1, Giuseppe Lippi 2 1 Scuola Superiore Sant Anna and Fondazione CNR Regione
More informationValidation of an accelerated high-sensitivity troponin T assay protocol in an Australian cohort with chest pain
Elevation of cardiac troponin (ctn) levels is central to the definition of acute myocardial infarction (AMI). 1 Increasingly sensitive ctn assays offer the potential for AMI to be diagnosed earlier than
More informationPerioperative Myocardial Infarction
Perioperative Myocardial Infarction Which patient should UNDERGO CORONARY ANGIOGRAPHY? The Cardiologists view Hans Rickli, St.Gallen 1 Experience Standards Risk stratification Team approach.. Tightrope
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationSpeaker: Richard Heitsman, MICT, C-POC-AACC. Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America.
Speaker: Richard Heitsman, MICT, C-POC-AACC Title: National Account Manager/Clinical Cardiac Specialist-Radiometer America. Upon completion the participant will be able to o Review current and evolving
More informationInternational Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp , September, ISSN:
International Journal of Cardiology and Cardiovascular Research Vol. 4(2), pp. 072-078, September, 2018. www.premierpublishers.org, ISSN: 3102-9869 IJCCR Research Article Copeptin as a Novel Biomarker
More informationRapid rule out of acute myocardial infarction: novel biomarker-based strategies
653229ACC0010.1177/2048872616653229European Heart Journal: Acute Cardiovascular CareMueller et al. research-article2016 Original scientific paper Rapid rule out of acute myocardial infarction: novel biomarker-based
More informationAbstract. Introduction. imedpub Journals
Research Article imedpub Journals www.imedpub.com DOI: 10.21767/2472-1646.100056 Could the Intra-Laboratory Inter-Identical- Instrument Bias Compromise the Interpretation of the Absolute High-Sensitive
More informationSupplemental Material
Supplemental Material Table of Contents Supplemental Methods... 2 Details on exclusion criteria... 2 Use of hs-ctnt for adjudication of final diagnoses... 2 Assumption of Linearity... 3 Investigational
More informationImproving the detection of myocardial infarction in women
Improving the detection of myocardial infarction in women British Cardiac Society Listening to the Female Voice 4 th June 2014 anoopsshah@gmail.com Dr Anoop Shah BHF Centre for Cardiovascular Sciences
More informationPerformance of the high-sensitivity troponin assay in diagnosing acute myocardial infarction: systematic review and meta-analysis
Performance of the high-sensitivity troponin assay in diagnosing acute myocardial infarction: systematic review and meta-analysis Ayman Al-Saleh MD, Ashraf Alazzoni MD, Saleh Al Shalash MD, Chenglin Ye
More informationBetter, higher, lower, faster: increasingly rapid clinical decision making using high-sensitivity cardiac troponin assays
Editorial Page 1 of 5 Better, higher, lower, faster: increasingly rapid clinical decision making using high-sensitivity cardiac troponin assays Noreen van der Linden, Alexander S. Streng, Will K. W. H.
More informationPeter A. Kavsak, 1* Andrew R. MacRae, 2 Glenn E. Palomaki, 3 Alice M. Newman, 4 Dennis T. Ko, 4 Viliam Lustig, 2 Jack V. Tu, 4 and Allan S.
Clinical Chemistry 52:11 2028 2035 (2006) Evidence-Based Laboratory Medicine and Test Utilization Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected
More informationPost-Procedural Myocardial Injury or Infarction
Post-Procedural Myocardial Injury or Infarction Hugo A Katus MD & Evangelos Giannitsis MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Conflict of Interest:
More informationThe Clinical Laboratory Working with Physicians to Improve Patient Care
The Clinical Laboratory Working with Physicians to Improve Patient Care Michael A. Pesce, PhD Professor Emeritus Columbia University Medical Center Department of Pathology and Cell Biology Objectives Troponin
More informationClinical Investigations
Clinical Investigations Prognostic Implications of Low Level Cardiac Troponin Elevation Using High-Sensitivity Cardiac Troponin T Address for correspondence: Marc P. Bonaca, MD TIMI Study Group/Cardiovascular
More informationPreoperative tests (update)
National Institute for Health and Care Excellence. Preoperative tests (update) Routine preoperative tests for elective surgery NICE guideline NG45 Appendix C: April 2016 Developed by the National Guideline
More informationRecent community campaigns on
Availability of highly sensitive troponin assays and acute coronary syndrome care: insights from the SNAPSHOT registry Use of hs troponin testing of patients hospitalised with possible ACS was associated
More informationPerioperative Infarcts: Epidemiology, predictors and post-op monitoring
Friday Nov 3rd, 2017 1pm Perioperative Infarcts: Epidemiology, predictors and post-op monitoring Dr Carol Chong Geriatrician Northern Health, Epping, Victoria, Australia How I became interested in this
More informationAnalytical performance of the i-stat cardiac troponin I assay
Clinica Chimica Acta 345 (2004) 123 127 www.elsevier.com/locate/clinchim Analytical performance of the i-stat cardiac troponin I assay Fred S. Apple a, *, MaryAnn M. Murakami a, Robert H. Christenson b,
More informationÄr dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationTiming of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism
7 Frederikus A. Klok Noortje van der Bijl Inge C.M. Mos Albert de Roos Lucia J. M. Kroft Menno V. Huisman Timing of NT-pro-BNP sampling for predicting adverse outcome after acute pulmonary embolism Letter
More informationNew diagnostic markers for acute coronary syndromes
New diagnostic markers for acute coronary syndromes - Nye diagnostiske markørerer for akutt iskemisk hjertesykdom Bertil Lindahl, Professor Cardiology, Uppsala University and Uppsala Clinical Research
More informationEffect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals
1 Effect of Short-term Maximal Exercise on BNP Plasma Levels in Healthy Individuals Jan Krupicka, MD, Tomas Janota, MD, Zdislava Kasalova, MD, Jaromir Hradec, MD 3rd Department of Internal Medicine, 1st
More informationPERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW
PERIOPERATIVE MYOCARDIAL INFARCTION THE ANAESTHESIOLOGIST'S VIEW Bruce Biccard Perioperative Research Group, Department of Anaesthetics 18 June 2015 Disclosure Research funding received Medical Research
More informationAbout OMICS International
About OMICS International OMICS International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS International hosts over 700
More informationTITLE: Cardiac Troponin for the Diagnosis of Acute Coronary Syndrome in the Emergency Department: A Review of Guidelines
TITLE: Cardiac Troponin for the Diagnosis of Acute Coronary Syndrome in the Emergency Department: A Review of Guidelines DATE: 11 January 2013 CONTEXT AND POLICY ISSUES Cardiac troponin (ctn) is a cardiomyocyte-specific
More informationBertil Lindahl Akademiska sjukhuset Uppsala
Bertil Lindahl Akademiska sjukhuset Uppsala Kriterier för akut hjärtinfarkt Bevis på myokardskada/nekros: Konstaterad höjning och/eller sänkning av biomarkörer (företrädesvis troponin) med minst ett värde
More informationAcute Coronary Syndromes
High-sensitivity Troponins Difficult Friends in Acute Coronary Syndromes Roland Klingenberg, Christian M Matter, 2 Christophe Wyss, Danielle Hof, Arnold von Eckardstein and Thomas F Lüscher 6. Clinical
More informationMyocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD
Myocardial Injury after Noncardiac Surgery (MINS): What is it and what can we do to help patients suffering this event? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting
More informationImpact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction
doi: 10.2169/internalmedicine.8510-16 http://internmed.jp ORIGINAL ARTICLE Impact of Aging on High-sensitivity Cardiac Troponin T in Patients Suspected of Acute Myocardial Infarction Taro Ichise, Hayato
More information9/18/2017. Disclosures. Cardiac Troponin: ER Utilization and the Next Generation
Disclosures Cardiac Troponin: ER Utilization and the Next Generation Joshua Soldo is an employee of Roche Diagnostics within the division of Medical Scientific Affairs. Data presented is intended for purely
More informationSerial Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction JAMA. 2011;306(24):
ORIGINAL CONTRIBUTION Serial Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction Till Keller, MD Tanja Zeller, PhD Francisco Ojeda, PhD Stergios Tzikas, MD Lars Lillpopp
More informationHow will new high sensitive troponins affect the criteria?
How will new high sensitive troponins affect the criteria? Hugo A Katus MD Abteilung Innere Medizin III Kardiologie, Angiologie, Pulmologie Universitätsklinikum Heidelberg Even more sensitive: The new
More informationRESPONSES TO COMMENTS ON: Recommendations for Use of Point-of-Care (POC) Troponin Assays in Assessment of Acute Coronary Syndrome
RESPONSES TO COMMENTS ON: Recommendations for Use of Point-of-Care (POC) Troponin Assays in Assessment of Acute Coronary Syndrome Page 1 Responses were received from: 1. Chemical Pathology Clinical Stream,
More informationPapers in Press. Published March 23, 2007 as doi: /clinchem
Papers in Press. Published March 23, 2007 as doi:10.1373/clinchem.2006.084715 The latest version is at http://www.clinchem.org/cgi/doi/10.1373/clinchem.2006.084715 Clinical Chemistry 53:4 547 551 (2007)
More informationPerioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE Trial
British Journal of Anaesthesia 115 (2): 227 33 (2015) doi: 10.1093/bja/aev137 Advance Access Publication Date 21 May 2015 Cardiovascular Perioperative myocardial injury in patients receiving cardiac output-guided
More informationCCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin
Canadian Society of Internal Medicine Annual Meeting 2017 Toronto, ON CCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin Dr. Vikas Tandon Associate Professor, Cardiology
More informationIntroduction. Key words: cardiac biomarkers; short-term mortality; perioperative risk; non-cardiac surgery; coronary artery disease
ISSN 2466-488X (Online) doi:10.5937/sjait1806117j Original work PREOPERATIVE HIGH-SENSITIVE TROPONIN T AND N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE IN PREDICTION OF SHORT-TERM MORTALITY AFTER NON-CARDIAC
More informationPredictive significance of detectable cardiac troponin I measured with a contemporary-sensitive assay in a real life experience
Original Article Page 1 of 5 Predictive significance of detectable cardiac troponin I measured with a contemporary-sensitive assay in a real life experience Laura Bonfanti 1, Giuseppe Lippi 2, Irene Ciullo
More informationWeekly and 90-Minute Biological Variations in Cardiac Troponin T and Cardiac Troponin I in Hemodialysis Patients and Healthy Controls
Papers in Press. Published March 11, 2014 as doi:10.1373/clinchem.2013.216978 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2013.216978 Clinical Chemistry 60:6 000 000 (2014)
More informationNeutrophil Gelatinase-Associated Lipocalin as a Biomarker of Acute Kidney Injury in Patients with Morbid Obesity Who Underwent Bariatric Surgery
Published online: October 31, 213 1664 5529/13/31 11$38./ This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial 3. Unported license (CC BY-NC) (www.karger.com/oa-license),
More informationEarly Goal-Directed Therapy
Early Goal-Directed Therapy Where do we stand? Jean-Daniel Chiche, MD PhD MICU & Dept of Host-Pathogen Interaction Hôpital Cochin & Institut Cochin, Paris-F Resuscitation targets in septic shock 1 The
More informationHigh-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study
DATA SUPPLEMENT High-sensitivity cardiac troponin and the under diagnosis of myocardial infarction in women: a prospective cohort study Anoop SV Shah, 1 Megan Griffiths, 1 Kuan Ken Lee, 1 David A McAllister,
More informationCLINICAL GUIDANCE FRAMEWORKS
IMPROVING CARE PROCESSES FOR PATIENTS WITH POSSIBLE SUSPECTED ACUTE CORONARY SYNDROME (ICARE-ACS): A NATIONAL IMPLEMENTATION TRIAL OF A CLINICAL GUIDANCE FRAMEWORK S Aldous; on behalf of the IcareACS team
More informationCongreso Nacional del Laboratorio Clínico 2016
Can biomarkers help us make a better use of cardiac imaging for myocardial ischaemia rule-out in the Emergency Department? Alessandro Sionis Director Acute and Intensive Cardiac Care Unit Hospital de la
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationJournal of Biostatistics and Epidemiology
Journal of Biostatistics and Epidemiology Original Article Usage of statistical methods and study designs in publication of specialty of general medicine and its secular changes Swati Patel 1*, Vipin Naik
More informationPerioperative increase in global blood flow to explicit defined goals and outcomes after surgery: a Cochrane Systematic Review
British Journal of Anaesthesia 111 (4): 535 48 (213) Advance Access publication 9 May 213. doi:1.193/bja/aet155 REVIEW ARTICLES Perioperative increase in global blood flow to explicit defined goals and
More informationCardiac troponin (ctn) testing is an
CLINICIAN UPDATE How to Interpret Elevated Cardiac Troponin Levels Vinay S. Mahajan, MD, PhD; Petr Jarolim, MD, PhD Cardiac troponin (ctn) testing is an essential component of the diagnostic workup and
More informationThe clinical performance of the novel POC Minicare ctni-assay. Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden
The clinical performance of the novel POC Minicare ctni-assay Per Venge, MD PhD Professor in Clinical Chemistry Uppsala University Uppsala, Sweden Disclosure: Per Venge has received consultancy honoraria
More informationAssays Pros and Cons AACB 2013 GOLD COAST QUEENSLAND AUSTRALIA
Highly Sensitive Versus Sensitive Troponin Assays Pros and Cons AACB 2013 GOLD COAST QUEENSLAND AUSTRALIA Robert H. Christenson, Ph.D., DABCC, FACB 2013 AACC President Professor of Pathology Professor
More informationJudicious Use of Preoperative Consultants. Relevant disclosures: None. Preoperative Consultation by Specialists: Overall Impact on Outcome?
Judicious Use of Preoperative Consultants Changing Practice of Anesthesia Meeting 2014 Relevant disclosures: None Rachel Eshima McKay, MD Professor, Anesthesia and Perioperative Director, UCSF Mount Zion
More information